Novo Nordisk
Correction due to missing pdf-file.
Bagsværd, Denmark, 25 March 2021 - Today, Novo
Nordisk A/S held its Annual General Meeting.
At the Annual General Meeting, Helge Lund, chair of the of Board of Directors stated: “In 2020, Novo Nordisk showed agility and resilience in very challenging times, and the COVID-19 pandemic has underscored the importance of continued innovation and relevance of businesses in times of crisis. We have delivered on our financial guidance and invested significantly in commercial launches and research and development. All in all, we are very satisfied with the progress made on our strategic aspirations, which has resulted in an attractive capital allocation to shareholders.” He continued: “Despite the pandemic and turbulent business environment, Novo Nordisk made important steps towards delivering on our purpose of driving change to defeat diabetes and other serious chronic diseases”.
Resolutions adopted at the Annual General Meeting
Financial year 2020 and board remuneration
Elections
Shares and capital
Other
COVID-19 situation
Due to the current COVID-19 pandemic and in order to minimise the spread of the virus, the meeting was held as a fully virtual meeting. Accordingly, shareholders attended by electronic means and had been encouraged to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual General Meeting.
Composition of the Board of Directors and its committees
After the Annual General Meeting, the Board of Directors held
a board meeting to appoint members of its committees.
The Board
of Directors, including its committees, is now composed as follows:
Novo Nordisk is a leading global healthcare company, founded in
1923 and headquartered in Denmark. Our purpose is to drive change to
defeat diabetes and other serious chronic diseases such as obesity
and rare blood and endocrine disorders. We do so by pioneering
scientific breakthroughs, expanding access to our medicines and
working to prevent and ultimately cure disease.
Novo Nordisk employs about 45,000 people in 80 countries and
markets its products in around 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed
on the New York Stock Exchange (NVO). For more information, visit
novonordisk.com
,
Facebook,
Twitter
,
LinkedIn
,
YouTube
.
Further information
Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com |
Michael Bachner (US) | +1 609 664 7308 | mzyb@novonordisk.com |
Investors: | ||
Daniel Muusmann Bohsen | +45 3075 2175 | dabo@novonordisk.com |
Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Mark Joseph Root | +45 3079 4211 | mjhr@novonordisk.com |
Kristoffer Due Berg (US) | +1 609 235 2989 | krdb@novonordisk.com |
Company announcement No 21 / 2021
Attachment